Validation of an LC–MS/MS method for the determination of sotorasib, a KRAS^G12C inhibitor, in human plasma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission impossible? Nat. Rev. Drug Discov. 13(11), 828–851 (2014).
  Medline CASGoogle Scholar
• 2. Dunnett-Kane V, Nicola P, Blackhall F, Lindsay C. Mechanisms of resistance to KRAS^G12C inhibitors. Cancers 13(1), 151 (2021).
  Medline CASGoogle Scholar
• 3. Hong DS, Fakih MG, Strickler JH et al. KRAS^G12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383(13), 1207–1217 (2020).
  Medline CASGoogle Scholar
• 4. Fernández-Medarde A, Santos E. RAS in cancer and development diseases. Genes Cancer 2, 344–358 (2011).
  Medline CASGoogle Scholar
• 5. Biernacka A, Tsongalis PD, Peterson JD et al. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genet. 209(5), 195–198 (2016).
  Medline CASGoogle Scholar
• 6. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging RAS back in the ring. Cancer Cell 25(3), 272–281 (2014).
  Medline CASGoogle Scholar
• 7. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol. Res. Pract. 205(12), 858–862 (2009).
  Medline CASGoogle Scholar
• 8. Jones RP, Sutton PA, Evans JP et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br. J. Cancer 116(7), 923–929 (2017).
  Medline CASGoogle Scholar
• 9. Wiesweg M, Kasper S, Worm K et al. Impact of RAS mutation subtype on clinical outcome – a cross-entity comparison of patients with advanced non-small lung cancer and colorectal cancer. Oncogene 38(16), 2953–2966 (2019).
  Medline CASGoogle Scholar
• 10. Canon J, Rex K, Saiki AY et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575(7781), 217–223 (2019). • Description of the discovery and optimization of AMG 510 as a clinical drug candidate.
  Medline CASGoogle Scholar
• 11. Blair HA. Sotorasib: first approval. Drugs 81, 1573–1579 (2021).
  Medline CASGoogle Scholar
• 12. FDA approves Lumakras™ (sotorasib). The first and only targeted treatment for patients with KRAS^G12C-mutated locally advanced or metastatic non-small cell lung cancer. Press release. www.prnewswire.com/news-releases/fda-approves-lumakras-sotorasib-the-first-and-only-targeted-treatment-for-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer-301301808.html
  Google Scholar
• 13. Nakajima EC, Drezner N, Li X et al. FDA approval summary: sotorasib for KRAS^G12C-mutated metastatic NSLC. Clin. Cancer Res. 28(8), 1482–1486 (2022). • Summary of the basis for US FDA accelerated approval of sotorasib.
  Medline CASGoogle Scholar
• 14. Guidance for Industry, Bioanalytical Method Validation. US FDA, Center for Drug Evaluation and Research, Center for Veterinary Medicine, MD, USA (2018).
  Google Scholar
• 15. Madhyastha N, Samantha SK, Dittakavi S et al. Validated HPLC–MS/MS method for quantitation of AMG 510, a KRAS^G12C inhibitor, in mouse plasma and its application to a pharmacokinetic study in mice. Biomed. Chromatogr. 35(4), e5043 (2021).
  Medline CASGoogle Scholar
• 16. Retmana IA, Loos NHC, Schinkel AH, Beijnen JH, Sparidans RW. Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography–tandem mass spectrometry. J. Chrom. B: Anal. Technol. Biomed. Life Sci. 1174, 122718 (2021).
  Medline CASGoogle Scholar
• 17. Du P, Liu L, Hu T, An Z. Integrative analysis of pharmacokinetic and metabolomic profiles for predicting metabolic phenotype and drug exposure caused by sotorasib in rats. Front. Oncol. 12, 778035 (2022).
  MedlineGoogle Scholar
• 18. Hughes NC, Bajaj N, Fan J, Wong EYK. Assessing the matrix effects of hemolyzed samples in bioanalysis. Bioanalysis 1(6), 1057–1066 (2009).
  CASGoogle Scholar
• 19. Mayrand-Provencher L, Furtado M, Mess JN, Dumont I, Garofolo F. Choosing the appropriate matrix to perform a scientifically meaningful lipemic plasma test in bioanalytical method validation. Bioanalysis 6(12), 1639–1646 (2014).
  CASGoogle Scholar
• 20. Werner JA, Davies R, Wahlstrom J et al. Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRAS^G12C, are associated with renal toxicity in the Sprague Dawley rat. Toxicol. Appl. Pharmacol. 423(13), 115578 (2021). • Study of sotorabsib metabolism associated with renal toxicity in rats.
  Medline CASGoogle Scholar
• 21. Dahal UP, Rock BM, Rodgers J, Shen X, Wang Z, Wahlstrom JL. Absorption, distribution, metabolism and excretion of [¹⁴C]-sotorasib in rats and dogs: interspecies differences in absorption, protein conjugation and metabolism. Drug Metab. Dispos. 50(5), 600–612 (2022). • Absorption, distribution, metabolism, excretion study of sotorasib in rats and dogs.
  Medline CASGoogle Scholar
• 22. Vuu I, Dahal UP, Wang Z et al. Absorption, metabolism and excretion of [¹⁴C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin–sotorasib conjugate. Cancer Chemother. Pharmacol. 90(4), 357–367 (2022). •• Characterization of the absorption, metabolism and excretion of sotorasib in humans.
  Medline CASGoogle Scholar
• 23. US FDA. NDA/BLA multi-disciplinary review and evaluation {NDA 214665} Lumakras™ (sotorasib). Application no. 214665Orig1s000. (2020). www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf
  Google Scholar